Positive opinion for retigabine in Europe

Positive opinion for retigabine in Europe

Meda's partner for retigabine, Valeant Pharmaceuticals International,
Inc., today announced that the European Medicines Agency's Committee for
Medicinal Products for Human Use (CHMP) has issued a positive opinion,
recommending marketing authorization for retigabine, named ezogabine in
the US, as an adjunctive (add-on) treatment of partial onset seizures,
with or without secondary generalisation in adults aged 18 years and
above with epilepsy.

For more information contact: Anders Larnholt, VP Corporate Development
& Investor Relations tel. +46 709 458 878